Prescient Therapeutics Ltd has released a press release.
PTX-100 receives U.S. FDA Fast Track Designation
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- PTX Opens First Clinical site for PTX-100 Phase 2a Study
- December 2024 Quarterly Update and Appendix 4C - amended
- December 2024 Quarterly Update and Appendix 4C
- US FDA allows PTX-100 Ph2 trial
- Appointment of Chief Executive Officer
Later from Prescient Therapeutics
- March 2025 Quarterly Update and Appendix 4C
- First Patient dosed for PTX-100 Phase 2a Study
- Prescient Therapeutics Launches Share Purchase Plan for $7m
- Prescient Therapeutics Opens Share Purchase Plan
- Prescient Therapeutics Extends Share Purchase Plan
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics